$ADVM
Adverum Biotechnologies, Inc. Stock $advm

$advm Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021777 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.90M	$13.35M	$11.35M
YoY Change	-12.86%	17.65%	53.59%
% of Gross Profit
Research & Development	$22.52M	$24.07M	$16.65M
YoY Change	-0.91%	44.53%	67.47%
% of Gross Profit
Depreciation & Amortization	$1.322M	$962.0K	$1.180M
YoY Change	22.41%	-18.47%	218.92%
% of Gross Profit
Operating Expenses	$34.42M	$38.52M	$28.00M
YoY Change	-5.39%	37.56%	61.56%
Operating Profit		-$38.52M	-$28.00M
YoY Change		37.56%	63.93%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$10.00K	$160.0K	$235.0K
YoY Change	-107.14%	-31.91%	-75.65%
Pretax Income	-$34.41M	-$38.36M	-$27.77M
YoY Change	-5.78%	38.14%	72.27%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$34.41M	-$38.36M	-$27.77M
YoY Change	-8.56%	38.15%	72.29%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.39	-$0.31
Diluted Earnings Per Share	-$350.2K	-$0.39	-$0.31
COMMON SHARES
Basic Shares Outstanding	98.15M shares	98.13M shares	88.87M shares
Diluted Shares Outstanding		98.13M shares	88.87M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$305.2M	$332.7M	$454.5M
YoY Change	-28.98%	-26.8%	180.56%
Cash & Equivalents	$34.20M	$32.97M	$72.70M
Short-Term Investments	$271.0M	$299.7M	$381.8M
Other Short-Term Assets	$6.248M	$7.764M	$5.200M
YoY Change	32.94%	49.31%	-7.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$317.1M	$347.8M	$459.7M
YoY Change	-27.0%	-24.34%	174.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.06M	$37.16M	$27.30M
YoY Change	19.24%	36.13%	79.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$250.0K	$138.0K	$19.00K
YoY Change	762.07%	626.32%	-88.41%
Total Long-Term Assets	$122.6M	$142.8M	$48.01M
YoY Change	154.69%	197.34%	26.6%
TOTAL ASSETS
Total Short-Term Assets	$317.1M	$347.8M	$459.7M
Total Long-Term Assets	$122.6M	$142.8M	$48.01M
Total Assets	$439.7M	$490.6M	$507.7M
YoY Change	-8.88%	-3.37%	147.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.387M	$2.517M	$3.034M
YoY Change	-50.64%	-17.04%	-10.29%
Accrued Expenses	$18.62M	$21.56M	$13.10M
YoY Change	2.85%	64.58%	-9.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.32M	$25.33M	$16.11M
YoY Change	2.15%	57.2%	-9.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.114M	$1.114M	$136.0K
YoY Change	0.0%	719.12%	-26.49%
Total Long-Term Liabilities	$1.114M	$1.114M	$136.0K
YoY Change	0.0%	719.12%	-26.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.32M	$25.33M	$16.11M
Total Long-Term Liabilities	$1.114M	$1.114M	$136.0K
Total Liabilities	$123.5M	$144.6M	$43.00M
YoY Change	156.2%	236.24%	4.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$648.1M	-$613.7M	-$464.9M
YoY Change	28.96%	32.01%	26.99%
Common Stock	$965.0M	$960.2M	$930.2M
YoY Change	2.97%	3.22%	75.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$316.2M	$346.0M	$464.7M
YoY Change
Total Liabilities & Shareholders Equity	$439.7M	$490.6M	$507.7M
YoY Change	-8.88%	-3.37%	147.03%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$34.41M	-$38.36M	-$27.77M
YoY Change	-8.56%	38.15%	72.29%
Depreciation, Depletion And Amortization	$1.322M	$962.0K	$1.180M
YoY Change	22.41%	-18.47%	218.92%
Cash From Operating Activities	-$25.81M	-$25.80M	-$26.55M
YoY Change	16.18%	-2.84%	178.59%
INVESTING ACTIVITIES
Capital Expenditures	-$4.352M	-$5.719M	-$3.080M
YoY Change	204.34%	85.68%	-50.24%
Acquisitions
YoY Change
Other Investing Activities	$28.24M	$16.19M	-$129.3M
YoY Change	117.03%	-112.52%	1364.21%
Cash From Investing Activities	$23.88M	$10.47M	-$132.4M
YoY Change	106.42%	-107.91%	781.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$200.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	375.0K	0.000	204.3M
YoY Change	-1.32%	-100.0%	-227044.44%
NET CHANGE
Cash From Operating Activities	-25.81M	-25.80M	-26.55M
Cash From Investing Activities	23.88M	10.47M	-132.4M
Cash From Financing Activities	375.0K	0.000	204.3M
Net Change In Cash	-1.557M	-15.33M	45.33M
YoY Change	-84.84%	-133.81%	-284.04%
FREE CASH FLOW
Cash From Operating Activities	-$25.81M	-$25.80M	-$26.55M
Capital Expenditures	-$4.352M	-$5.719M	-$3.080M
Free Cash Flow	-$21.46M	-$20.08M	-$23.47M
YoY Change	3.24%	-14.46%	602.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001501756
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36579
	dei	Entity Registrant Name EntityRegistrantName	Adverum Biotechnologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5258327
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 Saginaw Drive,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	656-9323
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	ADVM
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32971000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62424000	USD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98152090	shares
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	299734000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	367305000	USD
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	7358000	USD
CY2020Q4	us-gaap	Incentive To Lessee IncentiveToLessee	0	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7764000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4709000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	347827000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	434438000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100174000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19376000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37158000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5284000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	138000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2021Q3	us-gaap	Assets Assets	490581000	USD
CY2020Q4	us-gaap	Assets Assets	482567000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2517000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2810000	USD
CY2021Q3	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	18585000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4224000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4473000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25326000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20871000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	118141000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26235000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1114000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1114000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	144581000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	48220000	USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	960180000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	937134000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-523000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-261000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-613667000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-502536000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	346000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490581000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	482567000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24069000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16653000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	66657000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50581000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14453000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11351000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	52546000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30989000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	38522000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	28004000	USD
	us-gaap	Operating Expenses OperatingExpenses	119203000	USD
	us-gaap	Operating Expenses OperatingExpenses	81570000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-38522000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-28004000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-111703000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-81570000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	160000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	235000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	572000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1695000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-38362000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-27769000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-111131000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79875000	USD
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-55000	USD
CY2020Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-20000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-139000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	120000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-51000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	13000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-123000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38468000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27776000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111393000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79755000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98126000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98126000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88867000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88867000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97966000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97966000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80995000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80995000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7224000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1689000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000	USD
CY2021Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-33000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-22000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28436000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	414820000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8234000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	526000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-39000	USD
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-62000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-44333000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	379142000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5326000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-51000	USD
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-55000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-38362000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	346000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3409000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	332000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140873000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9650000	USD
CY2020Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	1922000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	303953000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4785000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	51000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2487000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	475000	USD
CY2020Q2	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	121000	USD
CY2020Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	41000	USD
CY2020Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	194000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-29200000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	282563000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6020000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	385000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	203383000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	516000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	13000	USD
CY2020Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-20000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-27769000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	464712000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-111131000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79875000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3323000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3081000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	20784000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14214000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2273000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	773000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1072000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	132000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-25000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3493000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5194000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	109000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000	USD
	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-2825000	USD
	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-1265000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-587000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1444000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3253000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-573000	USD
	advm	Increase Decrease In Lease Liabilities And Lease Incentive Receivable IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable	-94000	USD
	advm	Increase Decrease In Lease Liabilities And Lease Incentive Receivable IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable	-1061000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82016000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57067000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	328275000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	511845000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	384882000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	223765000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8990000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6748000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10771000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10411000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	481000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54826000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-291743000	USD
	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	1685000	USD
	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	344547000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12653000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2043000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	526000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	240000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	29000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2022000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	355609000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25168000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6799000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63423000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38255000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66896000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38255000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73695000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32971000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72696000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5284000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73695000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	84005000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2675000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	325000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-613700000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	332700000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2021Q3	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	27019000	USD
CY2021Q3	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2021Q3	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	0	USD
CY2020Q4	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2020Q4	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	3000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	27019000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	299762000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	18000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	46000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	299734000	USD
CY2020Q4	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	58894000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	58891000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	367191000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	121000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	367305000	USD
CY2021Q3	advm	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears	57400000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1100000	USD
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1100000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	800000	USD
CY2021Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	800000	USD
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	300000	USD
CY2021Q3	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	300000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	818000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	463000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6049000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	491000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13947000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	5844000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14405000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	6019000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14880000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	6200000	USD
CY2021Q3	advm	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	149252000	USD
CY2021Q3	advm	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	89136000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	199351000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	4400000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	400000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1300000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1100000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	8500000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	108153000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75629000	USD
CY2021Q3	us-gaap	Tenant Improvements TenantImprovements	30015000	USD
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	7358000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	101065000	USD
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	4300000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	600000	USD
CY2021Q3	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	5904000	USD
CY2020Q4	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	2844000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50483000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37797000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13325000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10072000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37158000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2021Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8557000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8344000	USD
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1249000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	40000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1075000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2326000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1285000	USD
CY2021Q3	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	18585000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10432000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.65
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6863000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.02
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.86
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3427000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.43
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13859000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.91
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5724000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.11
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5326000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6020000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20784000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14214000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1600000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16852000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10926000	shares

Files In Submission

Name	View Source	Status
0001628280-21-021777-index-headers.html	Edgar Link	pending
0001628280-21-021777-index.html	Edgar Link	pending
0001628280-21-021777.txt	Edgar Link	pending
0001628280-21-021777-xbrl.zip	Edgar Link	pending
advm-20210930.htm	Edgar Link	pending
advm-20210930.xsd	Edgar Link	pending
advm-20210930ex101thedinga.htm	Edgar Link	pending
advm-20210930ex102thedinga.htm	Edgar Link	pending
advm-20210930ex311.htm	Edgar Link	pending
advm-20210930ex312.htm	Edgar Link	pending
advm-20210930ex321.htm	Edgar Link	pending
advm-20210930ex322.htm	Edgar Link	pending
advm-20210930_cal.xml	Edgar Link	unprocessable
advm-20210930_def.xml	Edgar Link	unprocessable
advm-20210930_htm.xml	Edgar Link	completed
advm-20210930_lab.xml	Edgar Link	unprocessable
advm-20210930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADVM
Adverum Biotechnologies, Inc. Stock $advm

2021 Q4 Form 10-Q Financial Statement

#000162828021021777 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM Adverum Biotechnologies, Inc. Stock $advm

2021 Q4 Form 10-Q Financial Statement

#000162828021021777 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM
Adverum Biotechnologies, Inc. Stock $advm